Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TB Drug Development: An Attractive Public Health Project for FDA

This article was originally published in RPM Report

Executive Summary

FDA is joining in the push for new tuberculosis treatments, with Commissioner Hamburg lending support for a renewed development effort. The challenge is to translate podium appearances into changes that will make for a more attractive development pathway. The primary goal is to find a way to study multi-drug regimens, including regimens with more than one investigational compound. FDA is engaging on that thorny regulatory issue.

You may also be interested in...

J&J Bedaquline and the Evolving Role for Accelerated Approval: Confirming Safety, Not Efficacy?

Discussions during an advisory committee review Janssen’s TB drug bedaquiline showed some interesting thinking around accelerated approval and how much uncertainty can be acceptable—especially when it comes to safety.

J&J’s Bedaquiline: 10 Days Early For GAIN Incentive

Janssen Pharmaceuticals’ MDR-TB compound bedaquiline has the right indication to get an extra five years of exclusivity through the Generating Antibiotic Incentives Now Act – but the NDA was submitted too early to qualify.

FDA Catching Antibiotic Incentive Bug: Agency Primed To Consider Ways To Shorten Route for Resistant-Strain Drugs

FDA is working along a parallel path to other several other government agencies to find ways to stimulate drug development for anti-infectives active against resistant strains. Top policy leaders in the drug review divisions reflect the new interest by thinking aloud how historical controls or oncology-like accelerated approvals might speed the process.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts